148
Participants
Start Date
September 30, 2016
Primary Completion Date
June 30, 2017
Study Completion Date
June 30, 2017
LGD-6972-5 mg
5 mg LGD-6972 QD
LGD-6972-10 mg
10 mg LGD-6972 QD
LGD-6972-15 mg
15 mg LGD-6972 QD
Placebo
Placebo QD
Hopewell Junction
Manassas
Greensboro
Durham
Summerville
Orlando
Miami
Tampa
Brooksville
Tuscumbia
Munroe Falls
Franklin
Chicago
Carrollton
Dallas
Houston
Houston
Houston
Katy
Denver
Chandler
Surprise
Albuquerque
Las Vegas
Los Angeles
Huntington Park
North Hollywood
Montclair
San Diego
Lead Sponsor
Ligand Pharmaceuticals
INDUSTRY